文献速递炎症性肠病

生物制剂治疗未减少克罗恩病合并短肠综合征患者的手术

Treatment With Biologic Agents Has Not Reduced Surgeries Among Patients With Crohn's Disease With Short Bowel Syndrome.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-06-27

该研究基于美国全国住院患者样本中2,989,185例克罗恩病住院患者,比较生物制剂普及前(1993-1997年)与普及后(1998-2014年)小肠切除和医疗资源利用趋势。结果显示生物制剂时代整体切除比例显著下降,但合并短肠综合征与肠衰竭(SBS-IF)患者的切除比例无显著变化,且SBS-IF住院率上升、住院时间更长、总费用更高。

要点

  • 生物制剂普及后克罗恩病整体小肠切除比例显著下降,但合并SBS-IF患者无显著变化。
  • SBS-IF住院率从1998年16.5/1000住院升至2014年19.5/1000住院(P趋势<.01)。
  • SBS-IF住院与更长住院时间和更高总费用相关(P<.01)。

核心结论

  • 在美国人群中,使用生物制剂治疗克罗恩病降低了接受切除的患者比例,但在合并SBS-IF的患者中未降低。
  • 这些发现表明生物制剂减少了克罗恩病部分而非全部特征。
  • 需要研究识别SBS-IF风险患者、预防和治疗该并发症并寻找新治疗方法。

研究设计与样本

  • 基于美国全国住院患者样本的住院趋势分析,纳入2,989,185例克罗恩病住院患者。
  • 比较生物制剂治疗前时期(1993-1997年)与生物制剂治疗广泛使用后时期(1998-2014年)。
  • 采用泊松回归和线性回归分析小肠切除与医疗资源利用趋势。
  • 多变量模型校正年龄、性别、Charlson-Deyo合并症指数、支付来源、医院规模、地区及教学状态。

主要发现

  • 生物制剂治疗前时期切除比例从1993年121.8/1000住院至1997年110.1/1000住院,无显著变化(P趋势=.14)。
  • 生物制剂治疗开始后切除比例从1998年99.0/1000住院降至2014年64.6/1000住院,显著下降(P趋势<.01)。
  • 合并SBS-IF患者中,生物制剂治疗前时期切除比例从1993年0.7/1000住院至1997年0.7/1000住院(P趋势=.92),生物制剂治疗后时期从1998年0.6/1000住院至2014年0.7/1000住院(P趋势=.06),均无显著变化。
  • SBS-IF患者住院率从1998年16.5/1000住院升至2014年19.5/1000住院(P趋势<.01)。
  • SBS-IF住院与更长住院时间(P<.01)和更高总费用(P<.01)相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Little is known about the effects of biologic agents used to treat Crohn's disease (CD) on its long-term complications, such as short bowel syndrome and intestinal failure (SBS-IF). We evaluated trends in small bowel resections and health care utilization among patients with CD with and without SBS-IF. METHODS: We collected data on the National Inpatient Sample on 2,989,185 patients hospitalized with CD in the United States before the time period in which CD was treated with biologic agents (1993-1997) and after biologic therapy became widespread (1998-2014). We used Poisson and linear regression analyses to evaluate trends for small bowel resections and health care utilization among patients with CD with and without SBS-IF. Multivariable models were adjusted for age, sex, Charlson-Deyo comorbidity index, payer source, hospital size, region, and teaching status. RESULTS: The proportions of patients who underwent resection did not significantly change during the period before biologic therapy (121.8 per 1000 hospitalizations in 1993 to 110.1 per 1000 hospitalizations in 1997; P trend =.14) but decreased significantly during the period after biologic therapy began (99.0 per 1000 hospitalizations in 1998 to 64.6 per 1000 hospitalizations in 2014; P trend < .01). However, among patients with SBS-IF, similar proportions of patients underwent resection during the period before biologic therapy (0.7 per 1000 hospitalizations in 1993 to 0.7 per 1000 hospitalizations in 1997; P trend = .92) and during the period after biologic therapy (0.6 per 1000 hospitalizations in 1998 to 0.7 per 1000 hospitalizations in 2014; P trend = .06). Rates of hospitalization for patients with SBS-IF increased from 16.5 per 1000 hospitalizations in 1998 to 19.5 per 1000 hospitalizations in 2014 (P trend < .01). SBS-IF hospitalizations were associated with longer lengths of stay (P < .01) and greater total charges (P < .01). CONCLUSIONS: In a study of the United States population, we found that the use of biologic agents to treat CD reduced the proportion of patients undergoing resection, but not among patients with SBS-IF. These findings indicate that biologic agents reduce some but not all features of CD. Studies are needed to identify patients at risk for SBS-IF, prevent and treat this complication, and identify new treatments.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Limketkai BN, Parian AM, Chen PH, et al. Treatment With Biologic Agents Has Not Reduced Surgeries Among Patients With Crohn's Disease With Short Bowel Syndrome. Clin Gastroenterol Hepatol. 2017. PMID: 28666947. doi:10.1016/j.cgh.2017.06.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。